Bli medlem
Bli medlem

Du är här

2014-04-02

Aerocrine: NICE recommends the use of Exhaled Nitric Oxide (FeNO) testing to help diagnose and manage asthma.

Solna (Sweden) - Aerocrine AB (OMX Nordic Exchange: AERO) today
announced that NICE (National Institute for Health and Care
Excellence) has published guidelines
(http://www.nice.org.uk/newsroom/news/SimpleTestToHelpDiagnoseAndManageAs...)
recommending the use of Aerocrine's NIOX MINO® and NIOX VERO® to help
guide the diagnosis and management of asthma in both adults and
children.

NICE develops evidence-based guidelines that help the National Health
Services, local authorities and the wider medical community deliver
high-quality healthcare to the British public. The new guidelines
recommend that FeNO tests be used to assist with the diagnosis and
management of asthma caused by allergic airway inflammation in adults
and children who, after initial clinical examination, are considered
to have an intermediate probability of having asthma and when FeNO
testing is intended to be done in combination with other diagnostic
options.

Aerocrine's NIOX MINO and NIOX VERO measure FeNO levels. Healthcare
professionals use FeNO testing to identify allergic airway
inflammation in patients with suspected asthma, to help predict
patient response to corticosteroid therapy and to help assess patient
adherence to the prescribed therapy. NIOX MINO and NIOX VERO produce
objective, reliable and accurate results and are built on the
recommendations from the American Thoracic Society (ATS) and the
European Respiratory Society (ERS). FeNO measurement is also
recommended by NICE as an option to support asthma management in
people who are symptomatic despite using inhaled corticosteroids.

Professor Carole Longson, NICE Health Technology Evaluation Centre
Director, said: "Diagnosing asthma is often a very complicated and
lengthy process. Using these devices can provide additional
information for clinicians about those people who, following clinical
examination, are considered to have an intermediate probability of
having asthma.

Professor Longson added: "In people already diagnosed with asthma,
measuring nitric oxide levels to guide their asthma management is
likely to reduce asthma attacks. The measurements can reveal whether
they are taking their medication as prescribed."

The NICE report points out that poorly controlled asthma can have a
serious impact on the quality of life of the patient and their family
and that the use of FeNO testing in conjunction with existing tests
is more cost-effective than when the existing tests are used alone.

NICE's Diagnostics Advisory Committee, which is made up of leading
clinicians and academics, made its recommendations after hearing from
specialists that high FeNO levels in people with symptoms suggestive
of asthma, such as coughing or wheezing, may indicate that the
patient has eosinophilic asthma, which may be treated with inhaled
corticosteroids.

"The Committee heard from a patient expert that an accurate diagnosis
of asthma can sometimes take many years, resulting in less than
optimal treatment, which can have a direct impact on health. It was
also stated that FeNO-guided management could result in patients
better understanding their own condition and disease progression,
which could reduce hospitalisations and improve patient experience."

After hearing that approximately 30% of people do not take their
medications as prescribed, the NICE committee concluded that: "FeNO
testing could potentially enable patients and doctors to improve
treatment concordance in patients who are on medications for asthma."

Aerocrine's UK Managing Director David Plotts welcomed the latest NICE
guidelines. "Numerous studies across the world have concluded that
FeNO can be used to support more effective diagnosis and management
of asthma," he said. "Our NIOX MINO® and NIOX VERO® devices are
already in use by many GPs, nurses and specialist clinicians in both
primary and secondary care sites across the UK. "We now look forward
to more UK patients being able to gain access to this cutting-edge
method of testing airway inflammation and the benefits it can
provide."

Ian Pavord, Professor of Respiratory Medicine at the University of
Oxford, described the new recommendations as a "hugely significant
step forward for patients with asthma or those who are suspected of
having asthma."

Professor Pavord added that "using FeNO gives GPs, nurses and
specialist respiratory teams an important tool to identify
inflammation that is likely to respond to inhaled steroids. This is
often the key clinical question."

Aerocrine's CEO Scott Myers confirmed how important these
recommendations are both to the UK and other key markets "my belief
is that this will help accelerate the adoption of this technology
throughout the UK in second half of 2014 and early 2015 and will
provide the incentive for Clinical Commissioning Groups to seriously
consider supporting the FeNO test within their GP practices. These
factors should contribute to the positive growth of the UK market.
These recommendations are viewed by many countries who value the
process and credibility that NICE provides and is another step in
ensuring that FeNO is regarded as an integral part of standard asthma
care."

NICE has also developed tools including an implementation pack to
support the uptake and adoption of the technology across the NHS. The
implementation pack, which can be found at
http://guidance.nice.org.uk/DG12/AdoptionSupport includes case
studies from hospitals and GP surgeries that currently use NIOX MINO
and NIOX VERO and will contain useful information and practical
advice on putting this guidance into practice.

The full NICE guidance can be found at:
http://guidance.nice.org.uk/DG12/Guidance/pdf/English

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788
379, +970 368 0336

David Plotts, Vice President, UK Managing Director and EU/RoW Sales. +44 (0) 7891 433239

Dr. Kathy Rickard, Chief Medical Officer, Aerocrine AB +919 749 6708

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved
management and care of patients with inflammatory airway diseases. As
the pioneer and leader in technology to monitor and manage airway
inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both
products enable fast and reliable management of airway inflammation
and may therefore play a critical role in more effective diagnosis,
treatment and follow-up of patients with inflammatory airway diseases
such as asthma. Aerocrine is based in Sweden with subsidiaries in the
U.S., Germany and the U.K. Aerocrine shares were listed on the
Stockholm Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial
Instruments Trading Act. The information was submitted for
publication at 1:00 PM on 04/02/2014

-----------------------------------------------------------
http://news.cision.com/aerocrine/r/nice-recommends-the-use-of-exhaled-ni...
http://mb.cision.com/Main/49/9562545/228340.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.